A. Ducher

Modeling the Effect of DAV132, a Novel Colon‐Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers

A. Andremont, J. Guedj, F. Mentré, 2020, Clinical pharmacology and therapeutics.

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission.

T. Cokelaer, J. Meynard, A. Andremont, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics

H. Goossens, Mohamed Mysara, M. Bonten, 2021, Nature Communications.

Microbiota-based markers predictive of development of Clostridioides difficile infection

H. Goossens, Mohamed Mysara, M. Bonten, 2021, Nature Communications.

Protection of the Human Gut Microbiome From Antibiotics

E. Le Chatelier, S. Kennedy, F. Levenez, 2017, bioRxiv.

An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones

T. Louie, J. de Gunzburg, M. Wilcox, 2022, The Journal of antimicrobial chemotherapy.

Targeted adsorption of molecules in the colon with the novel adsorbent‐based Medicinal Product, DAV132: A proof of concept study in healthy subjects

J. de Gunzburg, W. Weitschies, A. Andremont, 2015, Journal of clinical pharmacology.

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial

S. Opal, D. Angus, T. Calandra, 2009, Critical care medicine.

Conformational variations of the medial epicondyle of the humerus: A case study of fusion anomaly on dry bones.

B. Foti, A. Ducher, E. Verna, 2023, Morphologie : bulletin de l'Association des anatomistes.

A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects

F. Mentré, J. Pinquier, M. Varastet, 2021, Clinical pharmacology in drug development.

High Acquisition Rate of ESBL-Producing Enterobacteriaceae among French Military 2 Personnel on Mission Abroad, without Evidence of Inter-Individual Transmission 3

T. Cokelaer, J. Meynard, A. Andremont, 2020 .

DAV132, an Adsorbent-Based Product, Protects the Gut Microbiome and Prevents Clostridium difficile Infections during Moxifloxacin Treatments

J. Doré, S. Kennedy, F. Levenez, 2015 .